Prognostic value of serum CA125 levels in diffuse large B-cell lymphoma: potential role of a new sex- and age-adjusted reference value.
CA125, a tumor marker normally used to follow the clinical course of ovarian cancer, also may have a role in lymphoma. All available series were analyzed using the standard reference value 35 U/ml, but age and sex may influence serum CA125 (sCA125) levels. We aim to study the prognostic value of serum CA125 (sCA125) levels in diffuse large B-cell lymphoma (DLBCL), considering the influence of age and sex on sCA125 levels. We investigated the relationship between sCA125 and clinical outcome after treatment in 42 patients with DLBCL, comparing both the standard (35 U/ml) and a new age and sex adjusted (sex/age-adjusted) reference value proposed by our group. We found that patients with elevated sCA125 levels had significantly more adverse prognostic factors at diagnosis, lower CR rates, higher relapse rates and worse survival. In the low-risk IPI categories, the presence of elevated sCA125 defined a particularly high-risk subgroup with poorer 3-year PFS when compared with patients with normal sCA125 levels. The use of a sex/age-adjusted reference value for sCA125 may increase the sensitivity to identify those patients with elevated sCA125 levels truly related to DLBCL activity.
Gutiérrez
Antonio
A
Service of Hematology, University Hospital Son Dureta, Palma de Mallorca, Balearic Islands, Spain. antoniom.gutierrez@ssib.es
Martínez-Serra
J
J
Barceló
B
B
Sampol
A
A
Viñas
L
L
González
G
G
Bea
M D
MD
Amat
J C
JC
Martín
J
J
Ramos
R
R
Bautista
A
A
Forteza-Rey
J
J
Rodríguez
J
J
Besalduch
J
J
D000328:Adult; D000367:Age Factors; D000368:Aged; D000369:Aged, 80 and over; D014408:Biomarkers, Tumor / Q000097:blood*; D018394:CA-125 Antigen / Q000097:blood*; D005260:Female; D006801:Humans; D016403:Lymphoma, Large B-Cell, Diffuse / Q000175:diagnosis*; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D012008:Recurrence; D012016:Reference Values; D012189:Retrospective Studies; D012737:Sex Factors; D016896:Treatment Outcome
D014408:Biomarkers, Tumor; D018394:CA-125 Antigen